NDV-HXP-S: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 28: | Line 28: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Butanvac embalagem.jpg|NDV-HXP-S | |||
File:João Doria anuncia a Butanvac.jpg|NDV-HXP-S | |||
</gallery> | |||
Latest revision as of 00:49, 20 February 2025
NDV-HXP-S is a COVID-19 vaccine candidate developed by the Government Pharmaceutical Organization (GPO) of Thailand. It is a protein subunit vaccine that uses a new technology involving the Newcastle Disease Virus (NDV) and the HexaPro (HXP) spike protein of the SARS-CoV-2 virus.
Development and Technology[edit]
The NDV-HXP-S vaccine uses a unique technology that combines the Newcastle Disease Virus (NDV) and the HexaPro (HXP) spike protein of the SARS-CoV-2 virus. The NDV is used as a vector to deliver the HXP spike protein into the body. This spike protein then triggers an immune response against the SARS-CoV-2 virus.
The vaccine is being developed by the Government Pharmaceutical Organization (GPO) of Thailand. The GPO is a state enterprise under the Ministry of Public Health that is responsible for the production and distribution of pharmaceutical products in Thailand.
Clinical Trials[edit]
The NDV-HXP-S vaccine has undergone several phases of clinical trials. The results of these trials have shown that the vaccine is safe and effective in preventing COVID-19. The vaccine has also been found to be effective against several variants of the SARS-CoV-2 virus.
Availability and Distribution[edit]
The NDV-HXP-S vaccine is currently available in Thailand. The GPO has plans to distribute the vaccine to other countries in the future.
